Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

Israel Diabetes Market Report 2023: Diabetes Initiatives in Israel Bolster Sector Growth

Published

on

<!– Name:DistributionId Value:8782093 –> <!– Name:EnableQuoteCarouselOnPnr Value:False –> <!– Name:IcbCode Value:2790 –> <!– Name:CustomerId Value:1026737 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:6f7cf655-5316-4e55-8904-c98cdad0259c –>

Dublin, March 06, 2023 (GLOBE NEWSWIRE) — The “Israel Diabetes Market, Size, Forecast 2023-2028, By Insulin Pump, CGM, Self-Monitoring Blood Device and Company Analysis” report has been added to ResearchAndMarkets.com’s offering.

Israel Diabetes market will reach US$ 457.5 Million by 2028, according to the publisher.

Diabetes affects an estimated 15-20% of the adult population of Israel, making it one of the highest rates in the world. Diabetes is a chronic disease marked by excessive amounts of glucose (sugar) in the blood, which can lead to long-term health concerns if not effectively controlled.

Type 2 Diabetes is a major Public Health Threat in Israel

Type 1 holds the minimum percentage in the Israel diabetes market. Type 2 diabetes is caused by the body’s ineffective use of Insulin, often resulting from excess body weight and physical inactivity. Israel Type 2 diabetes is considered an epidemic and is continuing on the rise. In Israel, the percentage of diabetes in the Arab population is twice that found in the Jewish population.

Also, Insulin dependent diabetics generally take Insulin by injection or using a pump. Diabetes can lead to cardiovascular disease, blindness, and kidney failure. Furthermore, Israel’s diabetes pandemic is a huge public health concern, and ongoing efforts are required to enhance access to care and support for persons with diabetes, as well as to avoid the condition in the first place.

Israel’s Diabetes Market is poised to grow at a CAGR of 3.22% by 2028

It is now treatable with insulin shots, but there is no cure. Diabetes Mellitus fatalities in Israel reached 1,913 in 2020, according to the World Health Organization. Despite the fact that Israel’s diabetes incidence is growing year after year, the World Bank estimates that diabetes prevalence will be 8.5% in 2021. Scientists in Israel found a treatment for Type 2 Diabetes in 2021. For four months, the mice maintained normal insulin levels with only one injection.

The Rising Prevalence of Diabetes in Israel will Increase demand for the Insulin Pump Market

The Israel Diabetes Market is divided into three categories based on devices: Glucose Monitoring (CGM), Self-Monitoring Blood Glucose (SMBG), and Insulin Pumps. Insulin pumps will have the largest market share in the next years, owing to the rising prevalence of Type 1 diabetes and the development of high-quality pumps using clever technologies such as Artificial Intelligence and Machine Learning. The development of very precise glucose sensors and blood monitoring devices has also raised the demand for effective insulin pumps.

Insulin pump therapy was created to give a more physiologic form of insulin administration to patients who require Insulin. For starters, the insulin pump only utilizes conventional Insulin or rapid-acting insulin analogs, which produce more consistent results.

Furthermore, SMBG and CMG will dominate the Israeli market in the future year. Higher rates of self-monitored blood glucose (SMBG) measurement, especially eight times per day or more, are linked to better health. However, repeated daily SMBG fingerpick testing has a number of drawbacks, including low compliance owing to pain and discomfort and erroneous readings due to poor user technique.

CGM devices, which detect glucose in the interstitial fluid, have shown to be more successful than SMBG in monitoring glucose levels. As a result, CGM devices are becoming more widely accepted as a standard of treatment for diabetes. In 2022, Israel’s Diabetes Market was estimated to be worth US$ 378.2 Million.

Diabetes Initiatives in Israel

The Pesach Segal Israeli Center for Diabetes Research and Policy is a world-class research, policy, and teaching facility in Israel. The Israeli Center for Diabetes Research and Policy aims to be a resource for action, information, and understanding about diabetes, its origins, complications, effects, preventative measures, and treatment. Furthermore, the center is active in diabetes prevention and care activities and research in the following areas: therapeutic education, health promotion, behavioral modification, disease self-management, diabetes education, patient participation, and digital health.

Clinics treating diabetes in Israel have a completely different approach to treatment. An innovative method is the treatment of diabetes by stem cells in Israel. They are building materials for treating many diseases, including diabetes. The use of the newest therapy methods, the development and use of effective drugs, and the conduct of diabetic symposiums allow us to consider Israel one of the world centers for disease control. Also, doctors have made progress in the treatment of diabetic Israel. The causes of the disease are eliminated, and general restorative and substitution therapy is performed.

Diabetes clinics in Israel handle patients in a distinct way. Stem cell treatment for diabetes is a novel method in Israel. They are used to treat a variety of diseases, including diabetes. Because of the utilization of cutting-edge therapeutic techniques, the development and usage of beneficial drugs, and the organization of diabetes symposiums, Israel is considered one of the world’s disease-control hotspots. Doctors have also made progress in treating diabetic Israelis. The sources of the disease are eliminated, and general restorative and replacement therapy are given.

Israel Segments Market based on Devices

1. Continuous Glucose Monitoring (CGM)
2. Self-Monitoring Blood Glucose (SMBG)
3. Insulin Pump

Israel Diabetes Sub-Segment Analysis
Segments Market based on Devices: Breakup into 3 parts

1. Continuous Glucose Monitoring (CGM)
2. Self-Monitoring Blood Glucose (SMBG)
3. Insulin Pump

Israel Diabetes Sub-Segment Analysis
1. Self-Monitoring Blood Glucose (SMBG) Device: Breakup into 5 parts

1. Test Strips Market
2. Lancet Market
3. Meter Market
4. Blood Glucose (SMBG) Users
5. Blood Glucose Devices Reimbursement

2. Continuous Glucose Monitoring (CGM): Breakup into 4 parts

1. Glucose Sensor Market
2. CGM Transmitter Market
3. CGM User
4. CGM Reimbursement

3. Insulin Pump Market: Breakup into 3 parts

1. Insulin Pump Market
2. Insulin Pump Users
3. Reimbursement Policies

Report Attribute Details
No. of Pages 120
Forecast Period 2022 – 2028
Estimated Market Value (USD) in 2022 $378.21 Million
Forecasted Market Value (USD) by 2028 $457.53 Million
Compound Annual Growth Rate 3.2%
Regions Covered Israel

Key Topics Covered:

1. Introduction

2. Research & Methodology

3. Executive Summary

4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges

5. Israel Diabetes Market

6. Israel Diabetes Population
6.1 Type 1 Diabetes
6.2 Type 2 Diabetes

7. Share Analysis – Israel Diabetes Market
7.1 By Types

8. Continuous Glucose Monitoring Market (CGM) – Israel Market & Users

9. Blood Glucose Device (SMBG) – Israel Market & Users

10. Insulin Pump – Israel Market & Users

11. Insulin Pump – Company Analysis

12. SMBG – Company Analysis

13. CGM – Company Analysis

Companies Mentioned

  • Medtronic
  • Insulet Corporation
  • Abbott Laboratories
  • DarioHealth Crop
  • Dexcom, Inc
  • Roche Diagnostic
  • Tandem Diabetes Care

For more information about this report visit https://www.researchandmarkets.com/r/dw6d67

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment


GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

Addverb Releases 2023 Sustainability Report Detailing Company’s Journey towards Technological Ecology

Published

on

addverb-releases-2023-sustainability-report-detailing-company’s-journey-towards-technological-ecology

Successfully achieving the FY22-23 Extended Producer Responsibility (EPR) target of 3 metric tonnesFulfilled 17% of energy demand from renewable sources in CY 2023Improvement of the power factor from 0.88 to 0.99 over two yearsNOIDA, India, April 30, 2024 /PRNewswire/ — Addverb, a global leader in robotics and automation, releases its first Sustainability Report titled ‘Technological Ecology’. The report is produced in accordance with GRI Universal Standards and incorporates Environment, Social, and Governance (ESG) factors underscoring Addverb’s unwavering dedication to sustainability and commitment. Reporting initiatives from January 1st to December 3st, 2023, the report showcases Addverb’s commitment to Technological Ecology, aiming to reduce ecological impact while contributing to the planet’s well-being.

The report can be accessed on the Company’s website.
Commenting on the release of the report, Mr. Sangeet Kumar, Co-founder and CEO, Addverb said, “Addverb harnesses solar energy, employs energy-efficient machinery, and integrates lean manufacturing practices to reduce Greenhouse gas (GHG) emissions and promote responsible power consumption. Our vision extends beyond product creation to embedding sustainability throughout our designs and manufacturing processes, focusing on ecological balance and technological advancements.”
Addverb is committed to mitigating environmental impact through proactive measures and innovation, including strategic tree-planting initiatives, green belt cultivation for ecological restoration, sustainable water management practices with a focus on groundwater recharge, and fostering an inclusive workplace environment through Diversity, Equity, and Inclusion (DEI) initiatives.
Addverb, through this report, reflects its unwavering dedication to sustainability, innovation, and responsible business practices. By prioritising environmental stewardship and social responsibility, the company continues to pave the way for a greener and a more sustainable future.
About Addverb
Founded in 2016, Addverb offers end-to-end robotics solutions for warehouses and industrial automation. Addverb is based in India, with R&D facilities in India and the US, and subsidiaries worldwide, including Australia, Singapore, the Netherlands, and the US. Its fleet of automated robots and material handling technologies, along with in-house system integration and software solutions, enhances warehouse operations’ efficiency and accuracy.
Addverb provides tailored automation solutions, with its self-manufactured products, and a wide range portfolio consisting of Autonomous Mobile Robots, Sorting Robots, Automated Storage and Retrieval Systems, and Picking Technologies, fuelled by enterprise software; with a range of 350+ customers like Coca-Cola, PepsiCo, Unilever, Reliance, DHL, Amazon, ITC to name a few.
For more information visit: www.addverb.com or connect on [email protected].  
Photo : https://mma.prnewswire.com/media/2399932/Bioretention_pond.jpg Logo : https://mma.prnewswire.com/media/2399931/Addverb_Logo.jpg
 

View original content:https://www.prnewswire.co.uk/news-releases/addverb-releases-2023-sustainability-report-detailing-companys-journey-towards-technological-ecology-302130075.html

Continue Reading

Artificial Intelligence

New Independent Study Shows 70% of Organizations Prioritize Gen AI for Boosting Employee Productivity

Published

on

new-independent-study-shows-70%-of-organizations-prioritize-gen-ai-for-boosting-employee-productivity

The exclusive study commissioned by Apexon reveals how organizations, particularly from more regulated industries, are seizing the GenAI advantageOver 50% of surveyed organizations are implementing Gen AI in their businessesSUNDERLAND, England, April 30, 2024 /PRNewswire/ —  Apexon, a digital-first technology services company, today unveiled key findings from a Forrester Opportunity Snapshot Study “Regulated Industries Are Making Generative AI Core to Their Digital Strategy.” The study commissioned by Apexon and conducted by Forrester Consulting highlights significant insights into the adoption, challenges, and future of Gen AI in highly regulated industries such as Financial Services, Healthcare and Life Sciences. A critical finding is that while organizational readiness may not impede Gen AI adoption, the absence of governance proves to be a significant barrier.

 
 
The study surveyed 125 US-based CXOs and key decision-makers responsible for AI strategy, representing organizations.
According to the findings, a significant 71% of organizations prefer to procure Gen AI solutions from technology vendors, underscoring the strategic shift towards leveraging external expertise for technological advancement. The findings also throw light on the transformative potential of Gen AI to enhance employee productivity and customer experience.
Key highlights from the study also include:
Enhancing employee productivity has emerged as the primary use case surpassing customer experience, traditionally the most prevalent industry use case. 70% of the surveyed organizations are directing their investments in Generative AI towards elevating employee efficiency for more impactful activities.Investments in building a strong Gen AI ecosystem are expected to increase significantly in 2025.Financial Services prioritize customer service improvements, while Healthcare Life Sciences focus on digital operations enhancement with Gen AI. “Generative AI is arguably the most disruptive technology, set to revolutionize industries and redefine work paradigms,” said Sriniketh Chakravarthi, Chief Executive Officer, Apexon. “This study has unearthed crucial insights for regulated industries aiming to harness Gen AI’s true potential. The findings underscore the importance of an effective AI governance program, a human-in-the-loop approach to manage accuracy risks and the pivot employees will make from routine to more strategic and creative elements of their work.”
Apexon’s Gen AI capabilities:
Specializing in customized Gen AI solutions, Apexon addresses unique organizational needs and industry challenges by leveraging deep industry domain knowledge and advanced AI/ML expertise to design contextualized, human-centric applications that drive real-world outcomes. Genysys, a proprietary platform by Apexon, combines over 10+ LLM models into a versatile platform, streamlining content creation and workflow while ensuring fast processing and minimal latency. It unlocks Generative AI’s full potential for innovative, tailored content, enhancing operational efficiency and engagement. 
Click here to download the full study, titled “Regulated Industries Are Making Generative AI Core to Their Digital Strategy,” and discover more insights.
About Apexon:
Apexon is a digital-first technology services firm specializing in accelerating business transformation and delivering human-centric digital experiences. For over 17 years, the company has been meeting clients wherever they are in the digital lifecycle and helping them outperform their competition through speed and innovation. Its reputation is built on a comprehensive suite of engineering services, a dedication to solving clients’ toughest technology problems, and a commitment to continuous improvement. The company focuses on three broad solution areas of digital services: Digital Experience, Data Services, and Digital Engineering and has deep expertise in BFSI, healthcare, and life sciences. Apexon is backed by Goldman Sachs Asset Management and Everstone Capital.
Learn how Apexon helps clients with their digital transformation journeys at www.apexon.com.
Logo: https://mma.prnewswire.com/media/2263554/4375910/Apexon_Logo.jpg
Media contact:[email protected] 

View original content:https://www.prnewswire.co.uk/news-releases/new-independent-study-shows-70-of-organizations-prioritize-gen-ai-for-boosting-employee-productivity-302130442.html

Continue Reading

Artificial Intelligence

Droit and FINBOURNE Partner to Deliver End-to-End Position Reporting Solution

Published

on

droit-and-finbourne-partner-to-deliver-end-to-end-position-reporting-solution

LONDON, April 30, 2024 /PRNewswire/ — Droit, a technology firm at the forefront of computational law and regulation, will partner with FINBOURNE Technology, a provider of cloud-based investment data management software, to launch an end-to-end position reporting solution for increased regulatory transparency.

Over one hundred global jurisdictions have position reporting obligations, requiring market participants to report equity and equity derivatives holdings to regulatory bodies; a process that is complex, time consuming and costly.
Droit and FINBOURNE come together to deliver a joint, full-stack solution to enable sell-side and buy-side institutions to manage disclosure obligations for long, short and takeover panel reporting. This new offering leverages FINBOURNE’s financial data management platform LUSID, embedded with Droit’s Position Reporting product which delivers clear determination of reporting obligations based on consensus interpretations of requirements from Endoxa, a consortium of six global financial institutions. 
The unified approach ensures consistency around complex regulatory interpretations, regulatory clarity and accuracy of reporting. As part of the joint solution, Droit translates and processes detailed guidelines from all major global jurisdictions, automating the decision-making process for shareholder disclosure reporting eligibility. For complete accountability, a traceable audit record is generated for each evaluated position.
With FINBOURNE’s advanced data transformation capabilities, the new end-to-end solution seamlessly maps the multiple data inputs needed to evaluate rules. Moreover, it simplifies workflow interactions via an intuitive interface, effectively mitigating operational, cost, and complexity challenges.
“Integrating Droit into LUSID means that together we are able to deliver a complete solution for position reporting. This partnership enhances our ability to safeguard asset managers by making sense of shareholder disclosure data when it comes to complex trading books and provide a level of granular reporting detail that is unmatched in the industry.” added Thomas McHugh, CEO and Co-founder, FINBOURNE Technology.
“By partnering with FINBOURNE, we are able to leverage consensus interpretation and industry best practice for position reporting for all market participants.  The asset management industry can directly benefit from the experience of their sell-side counterparties.” said Brock Arnason, Founder and Chief Executive Officer of Droit. “FINBOURNE’s platform, built specifically to support the volume and complexity of data that characterizes position reporting, integrated with our consensus-driven eligibility rules, offers firms unrivaled traceability, transparency, and auditability.”
About Droit
Droit is a technology firm at the forefront of computational law and regulation within finance and other domains. Founded in 2012, Droit counts many of the largest financial institutions as its clients. Its award-winning, patented platform Adept provides an implementation of regulatory rules reflecting industry consensus. The Adept platform processes tens of millions of inquiries a day, deciding in real-time which interactions are legally permissible across the globe. Adept is used by institutions to evaluate, with sub-millisecond latency, the full regulatory implications of any given interaction within their transactional infrastructure.
For more information visit droit.tech. To obtain more information about Droit’s products, please contact [email protected].
About FINBOURNE Technology 
FINBOURNE combines extensive technical expertise in financial services data management with a best-in-class, open, cloud–based investment management and servicing product ecosystem. By deploying our solutions, our clients can better aggregate, manage and utilise data across their organisations.
With operations across North America, Europe, Asia and Australia, FINBOURNE’s data management solutions help financial services firms improve their investment management and servicing capabilities.
FINBOURNE is trusted by some of the world’s leading financial services firms, including Fidelity International, London Stock Exchange Group, Baillie Gifford and Northern Trust. 
For more information on FINBOURNE Technology visit www.FINBOURNE.com or contact [email protected] 
Logo – https://mma.prnewswire.com/media/2016603/Droit_Logo.jpgLogo – https://mma.prnewswire.com/media/2400551/Finbourne_logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/droit-and-finbourne-partner-to-deliver-end-to-end-position-reporting-solution-302130494.html

Continue Reading
Advertisement
Advertisement

Latest News

Trending